Last edition
News about "Antisense oligonucleotide"
GSK Receives Japan's First Approval for Bepirovirsen as Functional Cure for Chronic Hepatitis B
Japan’s MHLW approves Hibsago for eligible adults with chronic hepatitis B, following Phase 3 data showing a 19 percent functional cure rate after six months of treatment.
Antisense Oligonucleotide | 25/08/2026 | By News Bureau | 164
BioMarin, n-Lorem Partner to Develop First Investigational Therapy for ReNU Syndrome
BioMarin and the n-Lorem Foundation have partnered to develop an investigational antisense oligonucleotide therapy targeting the most common genetic variant associated with ReNU syndrome, a rare neurodevelopmental disorder with no approved treatments.
Antisense Oligonucleotide | 28/07/2026 | By News Bureau
GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment
GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.
Antisense Oligonucleotide | 29/05/2026 | By News Bureau | 320
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy